<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01178671</url>
  </required_header>
  <id_info>
    <org_study_id>R34MH091336</org_study_id>
    <secondary_id>R34MH091336</secondary_id>
    <nct_id>NCT01178671</nct_id>
  </id_info>
  <brief_title>Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial</brief_title>
  <official_title>Combined Mirtazapine and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment of Post-traumatic Stress Disorder (PTSD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research Foundation for Mental Hygiene, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Research Foundation for Mental Hygiene, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to examine the efficacy of the combination of mirtazapine
      and sertraline in the treatment of posttraumatic stress disorder (PTSD). Sertraline is
      FDA-approved for PTSD, but it is often not fully effective. The combination of mirtazapine
      and serotonin reuptake inhibitors like sertraline has appeared highly effective in a related
      disorder -- depression.

      In this study, sixty patients with chronic PTSD will be randomized to treatment with either
      sertraline + mirtazapine or sertraline + placebo for 12 weeks. Patients who show at least a
      minimal response after 12 weeks will continue for another 12 weeks on the same treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This double-blind randomized controlled trial was conducted from January 2011 to February
      2014. To acquire a diverse sample, outpatients were recruited at an academic medical center
      and at a private mental health clinic with primarily Spanish-speaking patients. A single team
      of investigators conducted the trial at both settings. Individuals with chronic PTSD were
      randomly assigned to 24 weeks of double-blind treatment with sertraline plus mirtazapine or
      sertraline plus placebo. This study was conducted in compliance with the Code of Ethics of
      the World Medical Association (Declaration of Helsinki) and the standards established by an
      Institutional Review Board and by the National Institutes of Health. Informed consent was
      obtained from participants after the nature of the procedures was explained.

      Participants Participants were adults ages 18-75, referred by clinicians or responding to
      advertisements. After a preliminary telephone screening, eligibility was determined by
      clinical interview and confirmed by structured interview with trained raters using the
      Clinician-Administered PTSD Scale (CAPS) and the Structured Clinical Interview for DSM-IV
      Axis I Disorders -- Patient Edition. Participants had a principal Diagnostic and Statistical
      Manual of Mental Disorders, 4th Edition (DSM-IV) diagnosis of chronic PTSD of at least
      moderate severity (CAPS score â‰¥50), and English or Spanish fluency. Bilingual clinicians
      treated and assessed individuals with Spanish language preference. Exclusion criteria were
      significant suicidal ideation; lifetime psychotic disorder, bipolar disorder, organic mental
      disorder, or seizure disorder; alcohol or substance use disorder in the past 3 months;
      unstable medical illness; history of traumatic brain injury of greater than moderate
      severity; pregnancy or nursing; unwillingness to use contraception (for women of childbearing
      potential); prior nonresponse to sertraline or combined treatment, or intolerance of
      sertraline or mirtazapine); and psychotropic medication use during the prior 2 weeks (4 weeks
      for monoamine oxidase inhibitors or fluoxetine), except that zolpidem for insomnia was
      allowed up to three times per week during the week prior to randomization; psychotherapy
      initiated within 3 months before randomization. Concomitant psychotropic medications were not
      permitted during the study.

      Randomization and Blinding Randomization used randomly permuted blocks stratified by patient
      language preference (English vs. Spanish), implemented by the data manager who had no patient
      contact. Mirtazapine 15 mg capsules or matching placebo capsules were packaged by a
      pharmacist with no patient contact. Patients were reminded at each visit with the independent
      evaluator (IE) to not discuss medication or adverse events, and allocations were concealed
      from all research personnel throughout each patient's participation.

      Treatments A single psychiatrist saw each patient for medication management, with an initial
      visit of 45 minutes and subsequent 30 minute visits weekly for two weeks, biweekly through
      week 12, then at 4-week intervals. At each visit the psychiatrist assessed clinical
      improvement and adverse events. Mirtazapine/placebo was initiated at 30 mg (two capsules) at
      bedtime for four weeks, after which patients without significant adverse events and with
      persistent PTSD symptoms had dose increased to a maximum of 45 mg/day. Dose could be
      decreased for intolerable adverse events, to a minimum of 15mg/day. Sertraline was initiated
      at 25 mg/day for four days, then increased as tolerated to 50 mg/day for the remainder of
      Week 1, 100 mg/day for Weeks 2-4, 150 mg/d for Weeks 5-6, and then 200 mg/day. Dosage could
      be decreased as clinically indicated to a minimum of 50 mg/day. Compliance was assessed with
      patient diaries and pill counts.

      Patients who prematurely discontinued study medication were encouraged to return for all
      assessments through week 24.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PTSD Severity</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>PTSD severity will be measured by the Clinician-Administered Posttraumatic Stress Disorder Scale, from 0 (least severe) to 136 (most severe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Discontinuation of Study Treatment</measure>
    <time_frame>up to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alternative Measure of PTSD Severity</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>as measured by the Short Posttraumatic Stress Disorder Rating Interview, which rates severity of PTSD from 0 (least severe) to 32 (most severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTSD Self-rated Severity</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>as measured by the PTSD Checklist which rates severity of PTSD from 17 (least severe) to 85 (most severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Severity</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>as measured by the 17-item Hamilton Rating Scale for Depression, which rates severity of depression on a scale from 0 (least depression) to 50 (greatest depression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Status</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Responders defined by Clinician Administered Posttraumatic Stress Disorder Scale total score decreased by at least 30% compared with baseline and Clinical Global Impression improvement score of =1 or 2 at endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission Status</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Remitter as defined by Clinician Administered Posttraumatic Stress Disorders Scale total score &lt;20 at endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>as assessed by Side Effect Checklist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>as measured by Pittsburgh Sleep Quality Index, which rates severity of impairment in sleep quality from 0 (least impaired) to 21 (most impaired).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual Functioning</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>as measured by Arizona Sexual Experiences Scale, which rates impairment in sexual functioning from 5 (least impaired) to 30 (most impaired).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Sertraline and Mirtazapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flexible dose of both medications for up to 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sertraline and Sugar pill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sertraline and Sugar pill for up to 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirtazapine</intervention_name>
    <description>Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks</description>
    <arm_group_label>Sertraline and Mirtazapine</arm_group_label>
    <other_name>Remeron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks</description>
    <arm_group_label>Sertraline and Mirtazapine</arm_group_label>
    <arm_group_label>Sertraline and Sugar pill</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks</description>
    <arm_group_label>Sertraline and Sugar pill</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current primary diagnosis of chronic PTSD

          -  Fluent in English or Spanish

        Exclusion Criteria:

          -  Past or current schizophrenia, schizoaffective disorder, organic mental disorder,
             bipolar disorder, or antisocial personality disorder.

          -  Substance abuse of dependence diagnosis in past 3 months

          -  Suicidal ideation or behavior in past 6 months that poses a significant danger.

          -  Medical illness that could significant increase risk of sertraline and mirtazapine
             treatment or assessment of response

          -  History of traumatic brain injury of greater than mild severity

          -  History of seizure disorder (except febrile seizure in childhood)

          -  Currently taking medication which has been effective for patient's PTSD.

          -  Inability to tolerate or unwillingness to accept a drug-free period prior to beginning
             the study for certain psychiatric medications.

          -  History of inability to tolerate sertraline or mirtazapine or inadequate response to
             an adequate trial of combined treatment.

          -  Pregnancy, lactation; for women of childbearing potential, not using an effective
             birth control method.

          -  Current cognitive-behavioral therapy. Any psychotherapy initiated within 3 months of
             beginning this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franklin Schneier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anxiety Disorders Clinic, New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.columbiatrauma.org/</url>
    <description>The trauma program of the anxiety disorders clinic of New York State Psychiatric Institute/Columbia University. Click here for more information about this study:</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2010</study_first_submitted>
  <study_first_submitted_qc>August 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2010</study_first_posted>
  <results_first_submitted>December 8, 2015</results_first_submitted>
  <results_first_submitted_qc>January 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 29, 2016</results_first_posted>
  <last_update_submitted>April 2, 2016</last_update_submitted>
  <last_update_submitted_qc>April 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Research Foundation for Mental Hygiene, Inc.</investigator_affiliation>
    <investigator_full_name>Franklin Schneier</investigator_full_name>
    <investigator_title>Research Psychiatrist</investigator_title>
  </responsible_party>
  <keyword>PTSD</keyword>
  <keyword>trauma</keyword>
  <keyword>anxiety disorder</keyword>
  <keyword>medication</keyword>
  <keyword>sertraline</keyword>
  <keyword>mirtazapine</keyword>
  <keyword>pharmacotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Mianserin</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sertraline and Mirtazapine</title>
          <description>Flexible dose of both medications for up to 24 weeks
Mirtazapine: Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Sertraline and Sugar Pill</title>
          <description>Sertraline and Sugar pill for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
Sugar pill: Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sertraline and Mirtazapine</title>
          <description>Flexible dose of both medications for up to 24 weeks
Mirtazapine: Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Sertraline and Sugar Pill</title>
          <description>Sertraline and Sugar pill for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
Sugar pill: Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.6" spread="11.7"/>
                    <measurement group_id="B2" value="42.4" spread="13.3"/>
                    <measurement group_id="B3" value="40.0" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hamilton Rating Scale for Depression</title>
          <description>Measures severity of depression on scale from 0 (not depressed) to 50 (most severe).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.8" spread="6.2"/>
                    <measurement group_id="B2" value="20.4" spread="5.9"/>
                    <measurement group_id="B3" value="20.6" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Posttraumatic Stress Disorder Checklist</title>
          <description>Measures severity of posttraumatic stress disorder symptoms from 17 (mildest) to 85 (most severe).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.9" spread="11.0"/>
                    <measurement group_id="B2" value="60.0" spread="10.5"/>
                    <measurement group_id="B3" value="59.5" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quality of Life Enjoyment and Satisfaction Scale</title>
          <description>Measures quality of life from 16 (lowest quality) to 80 (greatest).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.1" spread="13.6"/>
                    <measurement group_id="B2" value="41.4" spread="13.5"/>
                    <measurement group_id="B3" value="40.2" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical Outcomes Study Short Form 12 - Physical</title>
          <description>Measures level of physical functioning from 0 (worst) to 100 (best).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.9" spread="9.8"/>
                    <measurement group_id="B2" value="41.4" spread="10.6"/>
                    <measurement group_id="B3" value="42.7" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical Outcomes Study Short Form 12 - Mental</title>
          <description>Measures level of mental functioning from 0 (worst) to 100 (best).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.3" spread="13.5"/>
                    <measurement group_id="B2" value="30.4" spread="10.0"/>
                    <measurement group_id="B3" value="30.4" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pittsburgh Sleep Quality Index Global</title>
          <description>Measures severity of sleep impairment from 0 (least impairment) to 21 (most severe).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.5" spread="4.9"/>
                    <measurement group_id="B2" value="12.8" spread="3.1"/>
                    <measurement group_id="B3" value="12.1" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pittsburgh Sleep Quality Index Addendum for PTSD</title>
          <description>Measure severity of sleep impairment related to posttraumatic stress disorder symptoms on a scale from 0 (least impairment) to 100 (most impairment)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.0" spread="4.9"/>
                    <measurement group_id="B2" value="11.2" spread="5.6"/>
                    <measurement group_id="B3" value="10.6" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinician Administered PTSD Scale</title>
          <description>Measures severity of posttraumatic stress disorder symptoms from 0 (least severe) to 136 (most severe).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.9" spread="19.5"/>
                    <measurement group_id="B2" value="81.3" spread="12.2"/>
                    <measurement group_id="B3" value="79.6" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PTSD Severity</title>
        <description>PTSD severity will be measured by the Clinician-Administered Posttraumatic Stress Disorder Scale, from 0 (least severe) to 136 (most severe).</description>
        <time_frame>up to 24 weeks</time_frame>
        <population>intention to treat sample</population>
        <group_list>
          <group group_id="O1">
            <title>Sertraline and Mirtazapine</title>
            <description>Flexible dose of both medications for up to 24 weeks
Mirtazapine: Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sertraline and Sugar Pill</title>
            <description>Sertraline and Sugar pill for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
Sugar pill: Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>PTSD Severity</title>
          <description>PTSD severity will be measured by the Clinician-Administered Posttraumatic Stress Disorder Scale, from 0 (least severe) to 136 (most severe).</description>
          <population>intention to treat sample</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" spread="17.4"/>
                    <measurement group_id="O2" value="34.6" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Discontinuation of Study Treatment</title>
        <time_frame>up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline and Mirtazapine</title>
            <description>Flexible dose of both medications for up to 24 weeks
Mirtazapine: Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sertraline and Sugar Pill</title>
            <description>Sertraline and Sugar pill for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
Sugar pill: Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discontinuation of Study Treatment</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.2" spread="73.1"/>
                    <measurement group_id="O2" value="90.0" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alternative Measure of PTSD Severity</title>
        <description>as measured by the Short Posttraumatic Stress Disorder Rating Interview, which rates severity of PTSD from 0 (least severe) to 32 (most severe)</description>
        <time_frame>up to 24 weeks</time_frame>
        <population>completers</population>
        <group_list>
          <group group_id="O1">
            <title>Sertraline and Mirtazapine</title>
            <description>Flexible dose of both medications for up to 24 weeks
Mirtazapine: Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sertraline and Sugar Pill</title>
            <description>Sertraline and Sugar pill for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
Sugar pill: Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Alternative Measure of PTSD Severity</title>
          <description>as measured by the Short Posttraumatic Stress Disorder Rating Interview, which rates severity of PTSD from 0 (least severe) to 32 (most severe)</description>
          <population>completers</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="2.9"/>
                    <measurement group_id="O2" value="6.7" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.14</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PTSD Self-rated Severity</title>
        <description>as measured by the PTSD Checklist which rates severity of PTSD from 17 (least severe) to 85 (most severe).</description>
        <time_frame>up to 24 weeks</time_frame>
        <population>completers</population>
        <group_list>
          <group group_id="O1">
            <title>Sertraline and Mirtazapine</title>
            <description>Flexible dose of both medications for up to 24 weeks
Mirtazapine: Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sertraline and Sugar Pill</title>
            <description>Sertraline and Sugar pill for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
Sugar pill: Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>PTSD Self-rated Severity</title>
          <description>as measured by the PTSD Checklist which rates severity of PTSD from 17 (least severe) to 85 (most severe).</description>
          <population>completers</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2" spread="18.4"/>
                    <measurement group_id="O2" value="39.2" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.50</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression Severity</title>
        <description>as measured by the 17-item Hamilton Rating Scale for Depression, which rates severity of depression on a scale from 0 (least depression) to 50 (greatest depression).</description>
        <time_frame>up to 24 weeks</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sertraline and Mirtazapine</title>
            <description>Flexible dose of both medications for up to 24 weeks
Mirtazapine: Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sertraline and Sugar Pill</title>
            <description>Sertraline and Sugar pill for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
Sugar pill: Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Depression Severity</title>
          <description>as measured by the 17-item Hamilton Rating Scale for Depression, which rates severity of depression on a scale from 0 (least depression) to 50 (greatest depression).</description>
          <population>intent to treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="6.1"/>
                    <measurement group_id="O2" value="11.6" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Status</title>
        <description>Responders defined by Clinician Administered Posttraumatic Stress Disorder Scale total score decreased by at least 30% compared with baseline and Clinical Global Impression improvement score of =1 or 2 at endpoint</description>
        <time_frame>up to 24 weeks</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sertraline and Mirtazapine</title>
            <description>Flexible dose of both medications for up to 24 weeks
Mirtazapine: Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sertraline and Sugar Pill</title>
            <description>Sertraline and Sugar pill for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
Sugar pill: Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Response Status</title>
          <description>Responders defined by Clinician Administered Posttraumatic Stress Disorder Scale total score decreased by at least 30% compared with baseline and Clinical Global Impression improvement score of =1 or 2 at endpoint</description>
          <population>intent to treat</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.8</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission Status</title>
        <description>Remitter as defined by Clinician Administered Posttraumatic Stress Disorders Scale total score &lt;20 at endpoint</description>
        <time_frame>up to 24 weeks</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sertraline and Mirtazapine</title>
            <description>Flexible dose of both medications for up to 24 weeks
Mirtazapine: Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sertraline and Sugar Pill</title>
            <description>Sertraline and Sugar pill for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
Sugar pill: Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Remission Status</title>
          <description>Remitter as defined by Clinician Administered Posttraumatic Stress Disorders Scale total score &lt;20 at endpoint</description>
          <population>intent to treat</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>19.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Effects</title>
        <description>as assessed by Side Effect Checklist</description>
        <time_frame>up to 24 weeks</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sertraline and Mirtazapine</title>
            <description>Flexible dose of both medications for up to 24 weeks
Mirtazapine: Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sertraline and Sugar Pill</title>
            <description>Sertraline and Sugar pill for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
Sugar pill: Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effects</title>
          <description>as assessed by Side Effect Checklist</description>
          <population>intent to treat</population>
          <units>percentage of subject dropped due to AEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality</title>
        <description>as measured by Pittsburgh Sleep Quality Index, which rates severity of impairment in sleep quality from 0 (least impaired) to 21 (most impaired).</description>
        <time_frame>up to 24 weeks</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sertraline and Mirtazapine</title>
            <description>Flexible dose of both medications for up to 24 weeks
Mirtazapine: Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sertraline and Sugar Pill</title>
            <description>Sertraline and Sugar pill for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
Sugar pill: Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality</title>
          <description>as measured by Pittsburgh Sleep Quality Index, which rates severity of impairment in sleep quality from 0 (least impaired) to 21 (most impaired).</description>
          <population>intent to treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="4.2"/>
                    <measurement group_id="O2" value="9.1" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sexual Functioning</title>
        <description>as measured by Arizona Sexual Experiences Scale, which rates impairment in sexual functioning from 5 (least impaired) to 30 (most impaired).</description>
        <time_frame>up to 24 weeks</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sertraline and Mirtazapine</title>
            <description>Flexible dose of both medications for up to 24 weeks
Mirtazapine: Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sertraline and Sugar Pill</title>
            <description>Sertraline and Sugar pill for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
Sugar pill: Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Sexual Functioning</title>
          <description>as measured by Arizona Sexual Experiences Scale, which rates impairment in sexual functioning from 5 (least impaired) to 30 (most impaired).</description>
          <population>intent to treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" spread="4.3"/>
                    <measurement group_id="O2" value="17.4" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sertraline and Mirtazapine</title>
          <description>Flexible dose of both medications for up to 24 weeks
Mirtazapine: Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Sertraline and Sugar Pill</title>
          <description>Sertraline and Sugar pill for up to 24 weeks
Sertraline: Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
Sugar pill: Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>bruising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>blurry vision</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>heartburn</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>emesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>restlessness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>nervousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>incoordination</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>forgetfulness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>impaired concentration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>apathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>decreased libido (men)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>decreased libido (women)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>sexual dysfunction (men)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>sexual dysfunction (women)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>sweating</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>skin problems</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>small sample due to low recruitment</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Franklin Schneier MD</name_or_title>
      <organization>Research Foundation for Mental Hygiene</organization>
      <phone>6467748041</phone>
      <email>fschneier@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

